Veracyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 07, 2023 at 04:10 pm EST
Share
Veracyte, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 4.08 million compared to USD 7.7 million a year ago. Revenue was USD 90.11 million compared to USD 75.59 million a year ago. Net loss was USD 29.62 million compared to USD 8.72 million a year ago. Basic loss per share from continuing operations was USD 0.41 compared to USD 0.12 a year ago.
For the nine months, sales was USD 14.77 million compared to USD 26.56 million a year ago. Revenue was USD 262.85 million compared to USD 216.24 million a year ago. Net loss was USD 46.11 million compared to USD 32.72 million a year ago. Basic loss per share from continuing operations was USD 0.64 compared to USD 0.46 a year ago.
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
VERACYTE, INC. 
